Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-06-13 00:00:00 ET · period of report 2022-06-10 · accession 0000886163-22-000078 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-13 | 2022-06-10 | LGND | Patel Sunil | Dir | A - Grant | $0.00 | +1,004 | 29.8K | +3% | $0 |
| D | 2022-06-13 | 2022-06-10 | LGND | Patel Sunil | Dir | A - Grant | $0.00 | +4,340 | 4,340 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-10 | A | A | 1,004 | $0.00 | 29,824 | D | — | — | (F1) Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. |
| 2 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-06-10 | A | A | 4,340 | $0.00 | 4,340 | D | $79.29 · — to 2032-06-10 | 4,340 Common Stock | (F2) Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. |